Jellagen Ltd announces a collaboration with the Mayo Clinic

▴ Jellagen Ltd announces a collaboration with the Mayo Clinic
Jellagen an innovative marine biotechnology comp[any makes collagen from jellyfish

Jellagen Limited, a marine biotechnology company producing high-value collagen derived from jellyfish, has entered into a licensing agreement to grant exclusive patent rights for the development to the Mayo Clinic treatment of vocal cord paralysis.

Vocal cord paralysis (VCP) is an injury to one or both of the recurrent laryngeal nerves (RLN) that control most of the muscles in the larynx, resulting in paralysis of the vocal cord muscles, which in turn can result in l airway obstruction, dyspnoea, vocal changes, etc. Vocal cord paralysis is caused by the side effects of surgery, trauma, cancer, and more.

The original text of this announcement, written in the source language, is the authentic official version. Translations are offered solely for the convenience of the reader and must refer to the original text, which is the only legally valid text.

Jellagen, an innovative marine biotechnology company was founded in 2015 by Professor Andrew Mearns Spragg, a Scottish marine biotechnology pioneer. The idea first came to Andrew whilst surfing off the East coast of Scotland in his youth swimming through blooms of jellyfish.

Due to human activity in the oceans, jellyfish populations are now blooming. The resulting explosion in jellyfish along coastal regions is causing increasing incidents of bathers being stung, offshore aquaculture collapse and in some cases power stations to be shut down due to water inlets becoming clogged.

In the early days, Jellagen operated out of a shed in Tenby but soon moved to the Bridge Innovation Centre at Pembroke Dock. The company continued to develop its business focused on new innovative manufacturing processes and developing new products using collagen derived from jellyfish to provide a next-generation collagen biomaterial.

From those early days, Jellagen has taken up additional space at Cardiff’s Capital Business Park where it commissioned the build and installation of a bespoke collagen manufacturing facility and Quality Control laboratory which were officially launched in May 2017.

Jellagen has secured considerable investment from both private investors and public sources to develop its business. In 2019, Jellagen commercialised its jellyfish collagen cell culture products for research.

If populations of jellyfish continue to rise globally we may need to get used to living in a gelatinous world.

Tags : #JellagenLtd #MayoClinic #Jellyfish #Collagen #LatestMarineBiotechnolohy #Biotechnology #CollagenfromJellyfish

About the Author

Team Medicircle

Related Stories

Loading Please wait...

Trending Now

Daily Covid-19 cases in US will hit six digits soon, warns expertsOctober 24, 2020
ICMR backed Covaxin could be ready by June 2021 ; Bharat BiotechOctober 24, 2020
Sewage signals early warning of coronavirus outbreaksOctober 24, 2020
U.S. sets single-day record for COVID-19 cases during new surgeOctober 24, 2020
Expert finds limited effectiveness of convalescent plasma for covid-19 patientsOctober 24, 2020
87 year old homeopathic doctor provides home visits to COVID-19 patients in Chandrapur district of MaharashtraOctober 24, 2020
Steroids boost survival of preterm babies in low-resource settings, new study findsOctober 24, 2020
Galera Therapeutics Announces Positive Interim Data from First Cohort of Patients in Pilot Phase 1/2 Clinical Trial of GC4419 in Pancreatic CancerOctober 24, 2020
FDA authorises restart of the COVID-19 AZD1222 vaccine US Phase III trialOctober 24, 2020
New Research Presented at Virtual ASTRO Meeting Supports Xoft System for Treatment of Early-Stage Breast Cancer and Gynecological CancersOctober 24, 2020
PMI Announces Medicago to Supply Up to 76 Million Doses of Its Plant-Derived COVID-19 Vaccine CandidateOctober 24, 2020
Gujarat records 1112 new cases of COVID-19 in last 24 hoursOctober 24, 2020
2377 COVID-19 patients recovered in Odisha in last 24 hoursOctober 24, 2020
Over 70 lakh people recovered from COVID-19 infection in country so farOctober 24, 2020
Health Minister Harsh Vardhan says next three months are crucial for country in fight against COVID-19October 24, 2020
Pfizer's Hospital Business section acquires Arixa Pharma October 24, 2020
India crosses the landmark of 10 crore total testsOctober 24, 2020
Bharat Biotech to conduct Phase 3 Trials Of Covaxin On 26,000 people across 25 sitesOctober 24, 2020
Catalent launches OptiGel DR, a delayed/enteric release Softgel October 24, 2020
Health Protection Campaign to be launched soon in ChhattisgarhOctober 24, 2020